TLP
APLS

Tri Locum Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Tri Locum Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,200
Closed -$889K – 51
2022
Q4 		$889K Buy
+17,200
New +$912K 0.36% 34

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's APLS Position: Q2 2023 in Review

Tri Locum Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 77,048 shares — an estimated $5.08M sold.

Tri Locum Partners first reported a position in APLS in Q4 2020 and held it in 4 quarters. The position peaked at $15M in Q4 2021. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Tri Locum Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Tri Locum Partners sold 77,048 Apellis Pharmaceuticals shares in Q2 2023, an estimated $5.08M.
  • Tri Locum Partners first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Tri Locum Partners's Apellis Pharmaceuticals position peaked at $15M in Q4 2021.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.